Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Uterine Cervical Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Leukemia 1Kidney Neoplasms 1Hypoxia 1Health Status Unknown 1Colonic Neoplasms 1Carcinoma in Situ 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

Rituximab 3Diphenhydramine 2Bendamustine Hydrochloride 2Acetaminophen 2obinutuzumab 1immunotoxin HA22 1ibrutinib 1fludarabine phosphate 1Vemurafenib 1Valganciclovir 1Therapeutics 1Specimen Handling 1Sodium Chloride 1Polymerase Chain Reaction 1Pentostatin 1Magnetic Resonance Imaging 1Histamine Antagonists 1High-Energy Shock Waves 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Famotidine 1Exercise Test 1Etoposide 1Epinephrine 1Electrocardiography 1Echocardiography 1Dexamethasone 1Cyclophosphamide 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Hairy Cell × Magnetic Resonance Imaging × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡